Business
SOHM Inc. Signs LOI to Acquire Stem Cell Disruptive Technology and Patents
SOHM Inc. Signs LOI to Acquire Stem Cell Disruptive Technology and Patents.
About this update from Sohm, Inc.
[{"type":"text","content":"CHINO HILLS, CA/ ACCESSWIRE/ / August 1, 2023 / SOHM, Inc. (OTC PINK:SHMN), a generic pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces today that the company has signed a letter of intent to acquire stem cell disruptive technology and patents called "ABBIE."SOHM, Inc. advisory board member Dr. David Aguilar, Ph.D., an innovator and owner of the technology and patents along with his partners, has submitted a letter of intent to SOHM Inc. regarding a potential acquisition of CGA Intellectual Holdings Inc. ("CGA") and its patented technology. CGA will provide cutting-edge stem cell regenerative, disruptive life science technology and related strategies, intended to create novel products and solutions in the regenerative medicine and cosmeceutical industries. The technology patents have been approved in China and are pending in the U.S., EU, Japan and South Korea.Dr. Aguilar explained that CGA's platform technology, termed "A Binding Based Integrating Enzyme" (ABBIE), combines the targetability of the Cas9 system with viral integrases as a fusion molecule intended for use in targeted integration experiments. Once validated, it is hypothesized that ABBIE methods for delivery of exogenous will circumvent pain points associated with current systems of gene editing, including haphazard viral delivery systems.Furthermore, Dr. Aguilar said, the CRISPR/Cas system provided an important step in improving the speed and accessibility of genome editing to a larger number of laboratories. New genome editing systems provide higher efficiency of recombination (or DNA insertion) and increased targetability as well as circumvent the need for endogenous host repair mechanisms such as non-homologous end joining (NHEJ) and homology directed recombination (HDR), which are important for the generation of novel cell-based therapies.Moreover, Dr. Aguilar added, the system can be engineered as "plug and play" simply by generating alternative donor DNA. The platform system will be utilized not only for human cell therapies but also for engineering plant DNA, potentially leading to increased generation of biofuel. The system can also be commercialized as a kit for off-the-shelf utility for clients such as universities, p...